Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients
Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.
How this was made
The 30-second read
Why it matters
The key tradable development is the FDA 510(k) and CLIA waiver submission supported by a large clinical enrollment and extensive PCR runs, which can improve odds of clearance and strengthen commercialization credibility. However, the company’s financials show continued heavy losses and declining cash, which can increase dilution or financing overhang.
Market read
Traders may reprice CODX on the probability-weighted path to FDA clearance, while also monitoring financing needs given the small revenue base and reduced cash.
What to watch
The article notes a private placement and cash decline; dilution risk and funding runway could dominate near-term price action even if FDA review proceeds smoothly.
Background
Co-Diagnostics is advancing an integrated molecular diagnostics ecosystem (instrumentation, assays, cloud connectivity, and manufacturing) and is now moving its Flu A/B & RSV test through FDA’s 510(k) pathway.
Ticker impact
Co-Diagnostics submitted an FDA 510(k) and CLIA waiver for its Co-Dx PCR Flu A/B & RSV test after enrolling 1,400+ patients.
Moderate upside bias on any follow-through toward FDA clearance, but near-term trading likely capped by very low current revenue and cash burn.
The article discloses a concrete regulatory step (510(k) plus CLIA waiver submission) and supporting study scale, but it also highlights limited revenue and declining cash, which can temper valuation reactions.
Market effects
Highlights ongoing FDA pathway progress for molecular diagnostics platforms, which can influence sentiment toward small-cap diagnostic developers.
MENA manufacturing and distribution expansion (Saudi, Mexico) supports longer-dated commercialization expectations but is not an immediate revenue driver.
TB and other infectious-disease assay development underscores continued demand for diagnostics, though the article’s immediate impact is company-specific regulatory progress.
Counterpoint
Despite the 510(k) submission, CODX’s revenue remains extremely small and cash fell sharply, so the market may discount regulatory progress until clearance or meaningful commercial traction appears.
Key entities
- companyCo-Diagnostics
Submitted FDA 510(k) and CLIA waiver for Co-Dx PCR Flu A/B & RSV test; reported Q2 2026 results and cash decline.
- regulatorFDA
Receives the 510(k) premarket notification for the Flu A/B & RSV test.
- regulatory_frameworkCLIA
CLIA waiver by application submitted concurrently with the 510(k).
